Sun Pharma Corporate Overview

Sales Breakup Q4 & FY21 SUN PHARMA (All Figures in Rs. Mn) Q4 FY21 Q4 FY20 CHANGE FY21 FY20 CHANGE Formulation India 26,709 23,648 12.9% 103,432 97,102 6.5% US 26,946 27,129 -0.7% 100,839 105,425 -4.4% Emerging Markets 14,015 13,540 3.5% 57,834 55,044 5.1% ROW 11,913 11,212 6.3% 48,191 45,210 6.6% Sub-total 79,583 75,529 5.4% 310,296 302,780 2.5% ÀPI Others 4,357 4,834 -9.9% 19,504 19,159 1.8% 374 417 -10.3% 1,593 1,312 21.4% Gross Sales 84,314 80,780 4.4% 331,392 323,252 2.5% US Formulations 32% 17% 29% 17% India Branded Generics Q4 Q4 Emerging Markets FY21 14% FY20 14% 5% 6% Rest of World 32% 34% API & Others © Sun Pharmaceutical Industries Limited. All Rights Reserved. # Includes Western Europe, Canada, Japan, Australia, New Zealand and other markets 49

View entire presentation